Simplified PESI (sPESI)
Simplified version of PESI using 6 binary variables to predict 30-day mortality after acute PE. Easier to calculate bedside than the original PESI.
Score interpretation
sPESI = 0: ~1.0% 30-day mortality. Low-risk PE.
→ Consider outpatient management if Hestia criteria negative, adequate home support. DOAC (rivaroxaban/apixaban). 24–48h follow-up arranged.
sPESI ≥ 1: ~10.9% 30-day mortality. Not low-risk.
→ Inpatient admission. Anticoagulate promptly. Assess for RV dysfunction (echo, troponin, BNP). Consider intermediate- or high-risk PE pathway.
Interpretation bands for the sPESI. Apply clinical judgement and local guidance.
References
- Jiménez D, et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010;170(15):1383–1389.
Related
Curated clinical cross-links plus same-class fallbacks.
- Nitric Oxide (Inhaled — iNO) · Selective Pulmonary Vasodilator
- Selexipag · Pulmonary Arterial Hypertension
- Macitentan · Pulmonary Arterial Hypertension
- Palivizumab · RSV Prophylaxis — Monthly Monoclonal Antibody (High-Risk Infants)
- Sildenafil (Paediatric — PPHN / PAH) · PDE5 Inhibitor (Paediatric Pulmonary Hypertension)
- Ziprasidone · Atypical Antipsychotic — D2/5-HT2A Antagonist (Low Metabolic Risk)
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.